Abciximab
Meloxicam may increase the anticoagulant activities of Abciximab.
Abiraterone
The serum concentration of Meloxicam can be increased when it is combined with Abiraterone.
Acebutolol
Meloxicam may decrease the antihypertensive activities of Acebutolol.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Meloxicam is combined with Aceclofenac.
Acemetacin
The risk or severity of adverse effects can be increased when Meloxicam is combined with Acemetacin.
Acenocoumarol
Meloxicam may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetaminophen
The risk or severity of adverse effects can be increased when Meloxicam is combined with Acetaminophen.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Acetylsalicylic acid.
Acetyl Sulfisoxazole
The metabolism of Meloxicam can be decreased when combined with Acetyl sulfisoxazole.
Advertisement
Aclarubicin
Meloxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Meloxicam.
Alclometasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.
Aliskiren
Meloxicam may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Meloxicam.
Alprenolol
Meloxicam may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Meloxicam.
Amcinonide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Amcinonide.
Amikacin
Meloxicam may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Meloxicam may decrease the antihypertensive activities of Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Aminosalicylic Acid.
Amiodarone
The metabolism of Meloxicam can be decreased when combined with Amiodarone.
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Meloxicam.
Ancrod
Meloxicam may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Meloxicam is combined with Androstenedione.
Anhydrous Tacrolimus
Meloxicam may increase the nephrotoxic activities of Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Meloxicam is combined with Antipyrine.
Antithrombin III
Meloxicam may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Meloxicam may increase the anticoagulant activities of Antithrombin III human.
Apalutamide
The serum concentration of Meloxicam can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Meloxicam.
Apixaban
Meloxicam may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Meloxicam is combined with Apremilast.
Aprepitant
The serum concentration of Meloxicam can be increased when it is combined with Aprepitant.
Arbekacin
Meloxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Meloxicam may increase the anticoagulant activities of Ardeparin.
Argatroban
Meloxicam may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Meloxicam may increase the anticoagulant activities of Argatroban.
Asenapine
Meloxicam may decrease the antihypertensive activities of Asenapine.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ginseng.
Aspirin
The risk or severity of adverse effects can be increased when Meloxicam is combined with Acetylsalicylic acid.
Atazanavir
The metabolism of Meloxicam can be decreased when combined with Atazanavir.
Atenolol
Meloxicam may decrease the antihypertensive activities of Atenolol.
Atomoxetine
The metabolism of Meloxicam can be decreased when combined with Atomoxetine.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Meloxicam.
azficel-T
The risk or severity of adverse effects can be increased when Meloxicam is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meloxicam.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meloxicam.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meloxicam.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Meloxicam.
Balsalazide
Meloxicam may increase the nephrotoxic activities of Balsalazide.
Bazedoxifene
Meloxicam may increase the thrombogenic activities of Bazedoxifene.
Becaplermin
Meloxicam may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meloxicam.
Benzthiazide
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Meloxicam.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Meloxicam.
Betamethasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Betamethasone.
Betaxolol
Meloxicam may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Meloxicam.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meloxicam.
Bisoprolol
Meloxicam may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Meloxicam may increase the anticoagulant activities of Bivalirudin.
Boceprevir
The metabolism of Meloxicam can be decreased when combined with Boceprevir.
Bopindolol
Meloxicam may decrease the antihypertensive activities of Bopindolol.
Bortezomib
The metabolism of Meloxicam can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Meloxicam can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Meloxicam can be decreased when it is combined with Bosentan.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Meloxicam.
Budesonide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Meloxicam is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Meloxicam.
Bupranolol
Meloxicam may decrease the antihypertensive activities of Bupranolol.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Meloxicam.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Meloxicam.
Capecitabine
The metabolism of Meloxicam can be decreased when combined with Capecitabine.
Capsaicin
The risk or severity of adverse effects can be increased when Meloxicam is combined with Capsaicin.
Captopril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Captopril.
Carbamazepine
The metabolism of Meloxicam can be increased when combined with Carbamazepine.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meloxicam.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meloxicam.
Carprofen
The risk or severity of adverse effects can be increased when Meloxicam is combined with Carprofen.
Carteolol
Meloxicam may decrease the antihypertensive activities of Carteolol.
Carvedilol
Meloxicam may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Meloxicam.
Celiprolol
Meloxicam may decrease the antihypertensive activities of Celiprolol.
Ceritinib
The serum concentration of Meloxicam can be increased when it is combined with Ceritinib.
Certoparin
Meloxicam may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Meloxicam.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam.
Chlorotrianisene
Meloxicam may increase the thrombogenic activities of Chlorotrianisene.
Chlorphenesin
The risk or severity of adverse effects can be increased when Meloxicam is combined with Chlorphenesin.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meloxicam.
Cholecalciferol
The metabolism of Meloxicam can be decreased when combined with Cholecalciferol.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Choline magnesium trisalicylate.
Ciclesonide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Cilazapril.
Cinoxacin
Meloxicam may increase the neuroexcitatory activities of Cinoxacin.
Ciprofloxacin
Meloxicam may increase the neuroexcitatory activities of Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Meloxicam is combined with Cisplatin.
Citalopram
Citalopram may increase the antiplatelet activities of Meloxicam.
Citric Acid
Meloxicam may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Meloxicam may increase the anticoagulant activities of Citric Acid.
Clarithromycin
The metabolism of Meloxicam can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Meloxicam can be decreased when combined with Clemastine.
Clobetasol
The risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Clodronic Acid.
Clofezone
The metabolism of Meloxicam can be decreased when combined with Rabeprazole.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Meloxicam.
Clotrimazole
The metabolism of Meloxicam can be decreased when combined with Clotrimazole.
Cobicistat
The metabolism of Meloxicam can be decreased when combined with Cobicistat.
Colesevelam
Colesevelam can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Meloxicam.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Cortisone acetate.
Crisaborole
The metabolism of Meloxicam can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Meloxicam can be decreased when combined with Crizotinib.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Meloxicam.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Meloxicam.
Cyclosporine
Meloxicam may increase the nephrotoxic activities of Cyclosporine.
Dabigatran Etexilate
Meloxicam may increase the anticoagulant activities of Dabigatran etexilate.
Dabrafenib
The serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib.
Dalteparin
Meloxicam may increase the anticoagulant activities of Dalteparin.
Danaparoid
Meloxicam may increase the anticoagulant activities of Danaparoid.
Darunavir
The metabolism of Meloxicam can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Meloxicam can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Meloxicam can be increased when it is combined with Dasatinib.
Daunorubicin
Meloxicam may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Deferasirox
The serum concentration of Meloxicam can be decreased when it is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Meloxicam is combined with Deflazacort.
Delavirdine
The metabolism of Meloxicam can be decreased when combined with Delavirdine.
Desipramine
Meloxicam may decrease the antihypertensive activities of Desipramine.
Desirudin
Meloxicam may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Meloxicam.
Dexamethasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meloxicam.
Dextran
Meloxicam may increase the anticoagulant activities of Dextran.
Dextran 40
Meloxicam may increase the anticoagulant activities of Dextran 40.
Dextran 70
Meloxicam may increase the anticoagulant activities of Dextran 70.
Dextran 75
Meloxicam may increase the anticoagulant activities of Dextran 75.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Meloxicam.
Dicumarol
Meloxicam may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Meloxicam may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Meloxicam may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Meloxicam is combined with Diflunisal.
Difluprednate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Meloxicam.
Dihydroergotamine
The metabolism of Meloxicam can be decreased when combined with Dihydroergotamine.
Dihydrostreptomycin
Meloxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Diltiazem
The metabolism of Meloxicam can be decreased when combined with Diltiazem.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Meloxicam.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meloxicam.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meloxicam.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Meloxicam.
Dothiepin
The metabolism of Meloxicam can be decreased when combined with Dosulepin.
Doxorubicin
Meloxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Doxorubicin Hydrochloride
Meloxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Doxycycline
The metabolism of Meloxicam can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Meloxicam can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Meloxicam can be decreased when combined with Dronedarone.
Drospirenone
Meloxicam may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Droxicam.
Duloxetine
Duloxetine may increase the antiplatelet activities of Meloxicam.
Edetic Acid
Meloxicam may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Meloxicam may increase the anticoagulant activities of Edoxaban.
Efavirenz
The metabolism of Meloxicam can be decreased when combined with Efavirenz.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Icosapent.
Enalapril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Meloxicam is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Meloxicam is combined with Enalaprilat.
Enoxacin
Meloxicam may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Meloxicam may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Meloxicam may increase the anticoagulant activities of Enoxaparin.
Enzalutamide
The serum concentration of Meloxicam can be decreased when it is combined with Enzalutamide.
Epirubicin
Meloxicam may decrease the excretion rate of Epirubicin which could result in a higher serum level.
Eplerenone
Meloxicam may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meloxicam.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Meloxicam.
Equol, (-)-
Meloxicam may increase the thrombogenic activities of Equol.
Erythromycin
The metabolism of Meloxicam can be decreased when combined with Erythromycin.
Escitalopram
Escitalopram may increase the antiplatelet activities of Meloxicam.
Esmolol
Meloxicam may decrease the antihypertensive activities of Esmolol.
Estradiol
Meloxicam may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Meloxicam may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Meloxicam may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Meloxicam may increase the thrombogenic activities of Estradiol valerate.
Estriol
Meloxicam may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Meloxicam may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Meloxicam may increase the thrombogenic activities of Estrogens, esterified.
Estrone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Meloxicam.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meloxicam.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meloxicam.
Ethinyl Estradiol
Meloxicam may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Meloxicam may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Meloxicam.
Etofenamate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Etofenamate.
Etoricoxib
The risk or severity of adverse effects can be increased when Meloxicam is combined with Etoricoxib.
Etravirine
The metabolism of Meloxicam can be decreased when combined with Etravirine.
Evening primrose oil
The risk or severity of adverse effects can be increased when Meloxicam is combined with Evening primrose oil.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Meloxicam.
Felodipine
The metabolism of Meloxicam can be decreased when combined with Felodipine.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Meloxicam.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Meloxicam.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Meloxicam.
Fish Oils
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fish oil.
Fleroxacin
Meloxicam may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Meloxicam.
Floxuridine
The metabolism of Meloxicam can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Meloxicam can be decreased when combined with Fluconazole.
Fludrocortisone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fludrocortisone.
Fluindione
Meloxicam may increase the anticoagulant activities of Fluindione.
Flumequine
Meloxicam may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Meloxicam is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluorometholone.
Fluorouracil
The metabolism of Meloxicam can be decreased when combined with Fluorouracil.
Fluoxetine
Fluoxetine may increase the antiplatelet activities of Meloxicam.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meloxicam.
Fluticasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluticasone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fluticasone propionate.
Fluvastatin
The metabolism of Meloxicam can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Meloxicam can be decreased when combined with Fluvoxamine.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Meloxicam.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Meloxicam.
Fondaparinux
Meloxicam may increase the anticoagulant activities of Fondaparinux.
Fondaparinux sodium
Meloxicam may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Meloxicam is combined with Formestane.
Fosamprenavir
The metabolism of Meloxicam can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Meloxicam can be increased when it is combined with Fosaprepitant.
Fosinopril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Fosinopril.
Fosphenytoin
The metabolism of Meloxicam can be increased when combined with Fosphenytoin.
Framycetin
Meloxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Meloxicam.
Fusidate
The serum concentration of Meloxicam can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Meloxicam can be increased when it is combined with Fusidic Acid.
Gatifloxacin
Meloxicam may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Meloxicam may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Meloxicam.
Gemfibrozil
The metabolism of Meloxicam can be decreased when combined with Gemfibrozil.
Gemifloxacin
Meloxicam may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Meloxicam may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Meloxicam may increase the thrombogenic activities of Genistein.
Gentamicin
Meloxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ginseng.
Grepafloxacin
Meloxicam may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.
Heparin
Meloxicam may increase the anticoagulant activities of Heparin.
Hydralazine
Meloxicam may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meloxicam.
Hydrocortisone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meloxicam.
Hypoxis hemerocallidea root extract
The serum concentration of Meloxicam can be decreased when it is combined with St. John's Wort.
Ibandronate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuprofen.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Meloxicam.
Idarubicin
Meloxicam may decrease the excretion rate of Idarubicin which could result in a higher serum level.
Idelalisib
The metabolism of Meloxicam can be decreased when combined with Idelalisib.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Meloxicam.
Imatinib
The metabolism of Meloxicam can be decreased when combined with Imatinib.
Imidapril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam.
Indinavir
The metabolism of Meloxicam can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Meloxicam can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Meloxicam is combined with Indobufen.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.
Irbesartan
The metabolism of Meloxicam can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Meloxicam can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Meloxicam can be decreased when combined with Isavuconazonium.
Isradipine
The metabolism of Meloxicam can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Meloxicam can be decreased when it is combined with Itraconazole.
Ivacaftor
The serum concentration of Meloxicam can be increased when it is combined with Ivacaftor.
Kanamycin
Meloxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Meloxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Kebuzone.
Ketoconazole
The metabolism of Meloxicam can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Meloxicam.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ginseng.
Labetalol
Meloxicam may decrease the antihypertensive activities of Labetalol.
Lapatinib
The metabolism of Meloxicam can be decreased when combined with Lapatinib.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Meloxicam.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Meloxicam.
Leflunomide
The metabolism of Meloxicam can be decreased when combined with Leflunomide.
Lepirudin
Meloxicam may increase the anticoagulant activities of Lepirudin.
Levobetaxolol
Meloxicam may decrease the antihypertensive activities of Levobetaxolol.
Levobunolol
Meloxicam may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Meloxicam may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Meloxicam may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Meloxicam.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Meloxicam.
Lisinopril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Meloxicam is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Meloxicam.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Meloxicam.
Lomefloxacin
Meloxicam may increase the neuroexcitatory activities of Lomefloxacin.
Lopinavir
The metabolism of Meloxicam can be decreased when combined with Lopinavir.
Lornoxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Lornoxicam.
Losartan
The metabolism of Meloxicam can be decreased when combined with Losartan.
Loteprednol
The risk or severity of adverse effects can be increased when Meloxicam is combined with Loteprednol.
Lovastatin
The metabolism of Meloxicam can be decreased when combined with Lovastatin.
Loxoprofen
The risk or severity of adverse effects can be increased when Meloxicam is combined with Loxoprofen.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meloxicam.
Luliconazole
The serum concentration of Meloxicam can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Meloxicam can be increased when it is combined with Lumacaftor.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Magnesium salicylate.
Manidipine
The metabolism of Meloxicam can be decreased when combined with Manidipine.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Meloxicam.
Meclofenamate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.
Medronate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meloxicam.
Mepindolol
Meloxicam may decrease the antihypertensive activities of Mepindolol.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Meloxicam.
Mestranol
Meloxicam may increase the thrombogenic activities of Mestranol.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Meloxicam.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.
Methylprednisolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Methylprednisolone.
Metipranolol
Meloxicam may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam.
Metoprolol
Meloxicam may decrease the antihypertensive activities of Metoprolol.
Metrizamide
Meloxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.
Midostaurin
The metabolism of Meloxicam can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Meloxicam can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the antiplatelet activities of Meloxicam.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Meloxicam.
Mitotane
The serum concentration of Meloxicam can be decreased when it is combined with Mitotane.
Moexipril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Meloxicam.
Moxifloxacin
Meloxicam may increase the neuroexcitatory activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Meloxicam.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meloxicam.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Mycophenolic acid.
Nabilone
The metabolism of Meloxicam can be decreased when combined with Nabilone.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Meloxicam.
Nadolol
Meloxicam may decrease the antihypertensive activities of Nadolol.
Nadroparin
Meloxicam may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Meloxicam.
Nalidixic Acid
Meloxicam may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Meloxicam.
Nebivolol
Meloxicam may decrease the antihypertensive activities of Nebivolol.
Nefazodone
The metabolism of Meloxicam can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Meloxicam can be decreased when combined with Nelfinavir.
Neomycin
Meloxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Meloxicam.
Netilmicin
Meloxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Netupitant
The serum concentration of Meloxicam can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Meloxicam can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Meloxicam can be decreased when combined with Nicardipine.
Niflumic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Niflumic Acid.
Nilotinib
The metabolism of Meloxicam can be decreased when combined with Nilotinib.
Nimesulide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Nimesulide.
Norfloxacin
Meloxicam may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Meloxicam is combined with Evening primrose oil.
Ofloxacin
Meloxicam may increase the neuroexcitatory activities of Ofloxacin.
Olaparib
The metabolism of Meloxicam can be decreased when combined with Olaparib.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Meloxicam.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Meloxicam.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Meloxicam.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Meloxicam is combined with Omacetaxine mepesuccinate.
Omeprazole
The metabolism of Meloxicam can be decreased when combined with Omeprazole.
Osimertinib
The serum concentration of Meloxicam can be increased when it is combined with Osimertinib.
Oxaprozin
The risk or severity of adverse effects can be increased when Meloxicam is combined with Oxaprozin.
Oxprenolol
Meloxicam may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Oxyphenbutazone.
Palbociclib
The serum concentration of Meloxicam can be increased when it is combined with Palbociclib.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Meloxicam.
Pamidronate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Pamidronate.
Paramethasone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Meloxicam is combined with Parecoxib.
Paromomycin
Meloxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
Paroxetine may increase the antiplatelet activities of Meloxicam.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Meloxicam.
Pefloxacin
Meloxicam may increase the neuroexcitatory activities of Pefloxacin.
Penbutolol
Meloxicam may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Meloxicam may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentobarbital
The metabolism of Meloxicam can be increased when combined with Pentobarbital.
Pentosan Polysulfate
Meloxicam may increase the anticoagulant activities of Pentosan Polysulfate.
Perindopril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Perindopril.
Phenindione
Meloxicam may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Meloxicam can be increased when combined with Phenobarbital.
Phenprocoumon
Meloxicam may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meloxicam.
Phenytoin
The metabolism of Meloxicam can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meloxicam.
Pindolol
Meloxicam may decrease the antihypertensive activities of Pindolol.
Pioglitazone
The metabolism of Meloxicam can be decreased when combined with Pioglitazone.
Pirarubicin
Meloxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Meloxicam.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Meloxicam.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.
Plazomicin
Meloxicam may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plicamycin
Meloxicam may decrease the excretion rate of Plicamycin which could result in a higher serum level.
Polyestradiol Phosphate
Meloxicam may increase the thrombogenic activities of Polyestradiol phosphate.
Polystyrene Sulfonate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Tolevamer.
Polystyrene Sulfonic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Tolevamer.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Meloxicam.
Pomalidomide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Pomalidomide.
Posaconazole
The metabolism of Meloxicam can be decreased when combined with Posaconazole.
Potassium Citrate
Meloxicam may increase the anticoagulant activities of Potassium Citrate.
Practolol
Meloxicam may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Meloxicam.
Prasterone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Pregnenolone.
Primidone
The metabolism of Meloxicam can be increased when combined with Primidone.
Probenecid
The serum concentration of Meloxicam can be increased when it is combined with Probenecid.
Promestriene
Meloxicam may increase the thrombogenic activities of Promestriene.
Propafenone
Meloxicam may decrease the antihypertensive activities of Propafenone.
Propranolol
Meloxicam may decrease the antihypertensive activities of Propranolol.
protein C, human
Meloxicam may increase the anticoagulant activities of Protein C.
protein S, human
Meloxicam may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Meloxicam may increase the anticoagulant activities of Protocatechualdehyde.
Pyrimethamine
The metabolism of Meloxicam can be decreased when combined with Pyrimethamine.
Quinapril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Quinapril.
Quinestrol
Meloxicam may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Meloxicam.
Quinine
The metabolism of Meloxicam can be decreased when combined with Quinine.
Rabeprazole
The metabolism of Meloxicam can be decreased when combined with Rabeprazole.
Ramipril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ramipril.
Ranolazine
The metabolism of Meloxicam can be decreased when combined with Ranolazine.
Rescinnamine
The risk or severity of adverse effects can be increased when Meloxicam is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol.
Reviparin
Meloxicam may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Meloxicam may increase the anticoagulant activities of Reviparin.
Rifabutin
The metabolism of Meloxicam can be increased when combined with Rifabutin.
Rifampin
The metabolism of Meloxicam can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Meloxicam can be increased when combined with Rifapentine.
Rimexolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Risedronate.
Rivaroxaban
Meloxicam may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Meloxicam is combined with Rofecoxib.
Rosiglitazone
The metabolism of Meloxicam can be decreased when combined with Rosiglitazone.
Rosoxacin
Meloxicam may increase the neuroexcitatory activities of Rosoxacin.
Rucaparib
The metabolism of Meloxicam can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Meloxicam.
Salicylamide
The risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylamide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylic acid.
Salsalate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Salsalate.
Saquinavir
The metabolism of Meloxicam can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Meloxicam can be decreased when combined with Saquinavir.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Meloxicam.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Meloxicam.
Secobarbital
The metabolism of Meloxicam can be increased when combined with Secobarbital.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Meloxicam is combined with Serrapeptase.
Sertraline
Sertraline may increase the antiplatelet activities of Meloxicam.
Sildenafil
The metabolism of Meloxicam can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Meloxicam can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Meloxicam can be increased when it is combined with Simeprevir.
Sisomicin
Meloxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Citrate
Meloxicam may increase the anticoagulant activities of Sodium Citrate.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Meloxicam.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Meloxicam.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Meloxicam.
Sorafenib
The metabolism of Meloxicam can be decreased when combined with Sorafenib.
Sotalol
Meloxicam may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Meloxicam may increase the neuroexcitatory activities of Sparfloxacin.
Spectinomycin
Meloxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.
Spirapril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Spirapril.
Spironolactone
Meloxicam may decrease the antihypertensive activities of Spironolactone.
ST. JOHN'S WORT EXTRACT
The serum concentration of Meloxicam can be decreased when it is combined with St. John's Wort.
Streptomycin
Meloxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin
Meloxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.
Sulfadiazine
The metabolism of Meloxicam can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Meloxicam can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meloxicam.
Sulfisoxazole
The metabolism of Meloxicam can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Meloxicam.
Suprofen
The risk or severity of adverse effects can be increased when Meloxicam is combined with Suprofen.
synthetic conjugated estrogens, A
Meloxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Meloxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Meloxicam may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Meloxicam.
Talinolol
Meloxicam may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Meloxicam.
Tamoxifen
The metabolism of Meloxicam can be decreased when combined with Tamoxifen.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Technetium Tc-99m medronate.
Telaprevir
The metabolism of Meloxicam can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Meloxicam can be decreased when combined with Telithromycin.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Meloxicam.
Temafloxacin
Meloxicam may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Meloxicam is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Meloxicam.
Terbutaline
Meloxicam may decrease the antihypertensive activities of Terbutaline.
Terbutaline Sulfate
Meloxicam may decrease the antihypertensive activities of Terbutaline.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Meloxicam.
Tertatolol
Meloxicam may decrease the antihypertensive activities of Tertatolol.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Tiaprofenic acid.
Tibolone
Meloxicam may increase the thrombogenic activities of Tibolone.
Ticagrelor
The metabolism of Meloxicam can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Meloxicam can be decreased when combined with Ticlopidine.
Tiludronate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Tiludronic acid.
Timolol
Meloxicam may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Meloxicam may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Meloxicam is combined with Tixocortol.
Tobramycin
Meloxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab
The serum concentration of Meloxicam can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Meloxicam can be decreased when combined with Tolbutamide.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Tolfenamic Acid.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Meloxicam.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Meloxicam.
Trandolapril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Meloxicam.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Meloxicam.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Meloxicam.
Triamcinolone
The risk or severity of adverse effects can be increased when Meloxicam is combined with Triamcinolone.
Triamterene
Meloxicam may decrease the antihypertensive activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Meloxicam.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meloxicam.
Trimethoprim
The metabolism of Meloxicam can be decreased when combined with Trimethoprim.
Trisodium Citrate Anhydrous
Meloxicam may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Meloxicam is combined with Trolamine salicylate.
Trovafloxacin
Meloxicam may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Meloxicam may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Meloxicam.
Valdecoxib
The risk or severity of adverse effects can be increased when Meloxicam is combined with Valdecoxib.
Valproate
The metabolism of Meloxicam can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Meloxicam can be decreased when combined with Valproic Acid.
Valrubicin
Meloxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.
Valsartan
The metabolism of Meloxicam can be decreased when combined with Valsartan.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Meloxicam.
Vemurafenib
The serum concentration of Meloxicam can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Meloxicam can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Meloxicam can be decreased when combined with Verapamil.
Voriconazole
The serum concentration of Meloxicam can be increased when it is combined with Voriconazole.
Warfarin
Meloxicam may increase the anticoagulant activities of Warfarin.
Zafirlukast
The metabolism of Meloxicam can be decreased when combined with Zafirlukast.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Meloxicam.
Ziprasidone
The metabolism of Meloxicam can be decreased when combined with Ziprasidone.
Zofenopril
The risk or severity of adverse effects can be increased when Meloxicam is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Meloxicam is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Meloxicam is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Meloxicam is combined with Zomepirac.
